» Articles » PMID: 37103364

The Blockade of Mitogen-Activated Protein Kinase 14 Activation by Marine Natural Product Crassolide Triggers ICD in Tumor Cells and Stimulates Anti-Tumor Immunity

Overview
Journal Mar Drugs
Publisher MDPI
Specialties Biology
Pharmacology
Date 2023 Apr 27
PMID 37103364
Authors
Affiliations
Soon will be listed here.
Abstract

Immunogenic cell death (ICD) refers to a type of cell death that stimulates immune responses. It is characterized by the surface exposure of damage-associated molecular patterns (DAMPs), which can facilitate the uptake of antigens by dendritic cells (DCs) and stimulate DC activation, resulting in T cell immunity. The activation of immune responses through ICD has been proposed as a promising approach for cancer immunotherapy. The marine natural product crassolide, a cembranolide isolated from the Formosan soft coral , has been shown to have cytotoxic effects on cancer cells. In this study, we investigated the effects of crassolide on the induction of ICD, the expression of immune checkpoint molecules and cell adhesion molecules, as well as tumor growth in a murine 4T1 mammary carcinoma model. Immunofluorescence staining for DAMP ectolocalization, Western blotting for protein expression and Z'-LYTE kinase assay for kinase activity were performed. The results showed that crassolide significantly increased ICD and slightly decreased the expression level of CD24 on the surface of murine mammary carcinoma cells. An orthotopic tumor engraftment of 4T1 carcinoma cells indicated that crassolide-treated tumor cell lysates stimulate anti-tumor immunity against tumor growth. Crassolide was also found to be a blocker of mitogen-activated protein kinase 14 activation. This study highlights the immunotherapeutic effects of crassolide on the activation of anticancer immune responses and suggests the potential clinical use of crassolide as a novel treatment for breast cancer.

Citing Articles

Soft coral Lobophytum crassum extract inhibits migration and induces apoptosis capabilities in human oral squamous cell carcinoma cells.

Wang S, Lu M, Hsu Y, Huang C, Fang C, Yu C J Dent Sci. 2025; 20(1):361-367.

PMID: 39873094 PMC: 11763181. DOI: 10.1016/j.jds.2024.06.016.


Natural products as promising modulators of breast cancer immunotherapy.

Alqathama A Front Immunol. 2024; 15:1410300.

PMID: 39050852 PMC: 11266008. DOI: 10.3389/fimmu.2024.1410300.

References
1.
Garg A, Maes H, van Vliet A, Agostinis P . Targeting the hallmarks of cancer with therapy-induced endoplasmic reticulum (ER) stress. Mol Cell Oncol. 2016; 2(1):e975089. PMC: 4905250. DOI: 10.4161/23723556.2014.975089. View

2.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

3.
Ishida Y, Agata Y, Shibahara K, Honjo T . Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992; 11(11):3887-95. PMC: 556898. DOI: 10.1002/j.1460-2075.1992.tb05481.x. View

4.
Kroemer G, Galluzzi L, Kepp O, Zitvogel L . Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2012; 31:51-72. DOI: 10.1146/annurev-immunol-032712-100008. View

5.
Lin C, Chang Y, Lin S, Su J, Chao Y, Tang K . Crassolide Suppresses Dendritic Cell Maturation and Attenuates Experimental Antiphospholipid Syndrome. Molecules. 2021; 26(9). PMC: 8123116. DOI: 10.3390/molecules26092492. View